Liver Soup Jiangzhuo Clinical Research, Primary Hypertension And Metabolic Syndrome

Hypertension is the major risk factor of coronary heart disease and stroke.According to recently published prospective study,of the population incidence of ischemic cardiovascular diseases,33% were due to hypertension, 30% were due to smoking tobacco,10% were due to high cholesterol,3% were due to diabetes and 24% attributed to other factors.This year the United States of America announced a large-scale epidemiological studies on the results of metabolic syndrome that hypertension is the most important "contributor"of many elements of metabolic syndrome.Compared with the normal population, high blood pressure in patients with metabolic syndrome is more popular. What kind of treatment modalities should we establish to get better treatment of hypertension and metabolic syndrome,and more effectively reduce cardiovascular risk? UKPDS Studies have shown that enhanced blood pressure control is more important on the prognosis of metabolic syndrome between enhanced control of blood glucose (glycosylated hemoglobin 7.9%-7.0%) and control blood pressure (diastolic blood pressure 87-82 mmHg).The result of intensive glycemic control is only moderately reduced microvascular end point, but continued follow-up to 10 years, renal function, retinopathy, still no significant improvement in mortality, however, strengthening the control of blood pressure, can lower the risk of cardiovascular events and mortality 2 to 4 times, and in reducing microvascular events, the effect of blood pressure control is more pronounced than blood glucose control. Lfestyle intervention is currently more used in the treatment of MS.The comprehensive treatment of blood pressur,blood sugar,lipids and body weight control can prevent and control MS,which can reduce cardiovascular and cerebrovascular disease, but it has not achieved satisfactory results.Many studies suggest that inflammation plays an important role in the development process of atherosclerosis and its complications.CRP is the most powerful predictor of cardiovascular risk markers of inflammation. Many studies reported that CRP increased significantly in high blood pressure and metabolic syndrome.So it is important that CRP changes when determining treatment effect of hypertension and metabolic syndrome.In summary, the patients with essential hypertension complicated by metabolic syndrome are recruited for the study of the phase, and we highlight the importance of controlling blood pressure.We distinguish the syndrome of hypertension and metabolic syndrome on the major aspects of the liver yang and liver spleen astagnation as the basis for the liver and stomach damp.We used an experienced formula-Jiangzhuo Qinggan formula to treat this disease and verify its effects. Aim:To explore the clinical efficacy and safety of Jiangzhuo Qinggan formula in the treatment of essential hypertension with metabolic syndromeMethods:44 patients with with hypertension and metabolic syndrome (damp-heat in liver and stomach) were randomly divided into treatment group(n=22) and control group(n=22).2 groups patients were taken to lifestyle intervention.The treatment group was given Jiangzhuo Qinggan formula,and the control group was given Irbesartan for a course of 4 weeks.Before and after treatment of blood pressure, changes in traditional Chinese medicine symptom score, H-CRP, GLU, CHO, TG, HDL-C, LDL-C and body mass index, waist-hip ratio and other changes are to determine the clinical efficacy.Before and after treatment of breathing, heart rate, CR, BUN, UA, ALT and AST,WBC RBC,HGB,K+,ECG are to determine drug safety.Results:①The 2 groups of drugs can improve systolic and diastolic blood pressure before and after treatment(P<0.01). Between the two groups, there is no difference in systolic and diastolic blood pressure after treatment(P> 0.05).②Total effective rate of treatment group in improving blood pressure was 86.36%, and that of control group was 54.55%.There is significant difference between the 2 groups(P<0.05).③The drugs of treatment group can improve the syndromes of headache and dizziness stretching, epigastric pain full, bitter mouth, dry throat, irritability, sticky stool. The drug of control group can improve the syndromes of headache and dizziness stretching,throat and irritability after treatment, statistically significant (p<0.05).After treatment,the syndromes of headache and dizziness stretching, epigastric pain full, mouth pain, irritability, sticky stool were improved. There were significant difference between pretreatment and posttreatment (p<0.05).④Total effective rate of treatment group was 95.45% and total effective rate of control group was 72.73%.There is significant difference between the 2 groups(P<0.05).⑤The drugs of treatment group can't improve H-CRP,TG,LDL-C,HDL-C,CHO,GLU,and there is no difference between pretreatment and posttreatment(P>0.05).The drugs of control group can't improve H-CRP,TG,LDL-C,HDL-C,CHO,GLU,and there is no difference between pretreatment and posttreatment P>0.05).⑥There are no difference between pretreatment and posttreatment in CR,BUN,UA,ALT,AST,WBC,RBC,HGB,PLT,K+,frequency of breath,heart rate and ECG(P>0.05).Conclusion:①Jiangzhuo Qinggan formula can improve systolic and diastolic blood pressure more significant than Irbesartan tablets.②Jiangzhuo Qinggan formula can improve the syndromes of headache and dizziness stretching, epigastric pain full, bitter mouth, dry throat, irritability, sticky stool.③Jiangzhuo Qinggan formula can't improve the level of H-CRP, GLU, CHO, TG, HDL-C,LDL-C,mass index and waist-to-hipratio.④Jiangzhuo Qinggan formula is a safe drug in clinic.